People: AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,394.50GBp
6:05am EST
Change (% chg)

-37.00p (-0.83%)
Prev Close
4,431.50p
Open
4,445.00p
Day's High
4,449.00p
Day's Low
4,390.00p
Volume
610,013
Avg. Vol
2,507,812
52-wk High
4,946.41p
52-wk Low
3,718.50p

Search Stocks

Soriot, Pascal 

Brief Biography

Pascal Soriot is the Executive Director and Chief Executive Officer of AstraZeneca PLC. Pascal was appointed as a Director and CEO in October 2012. From 2010 to September 2012, he served as Chief Operating Officer of Roche AG’s pharmaceuticals division. Prior to that, he was CEO of Genentech, a biologics business, and led its successful merger with Roche. He joined the pharmaceutical industry in 1986 and has worked in senior management roles throughout the world in a number of major companies. He brings to AstraZeneca a significant breadth of experience in both established and emerging markets, strength of strategic thinking, a successful track record of managing change and putting strategy into operation, and the ability to lead a diverse organisation, having lived in Australia, Japan, the US and Europe. He is a doctor of veterinary medicine (École Nationale Vétérinaire d’Alfort, Maisons-Alfort) and holds an MBA from HEC, Paris.

Basic Compensation

Total Annual Compensation, GBP Long-Term Incentive Plans, GBP All Other, GBP Fiscal Year Total, GBP
2,970,000 -- 374,000 3,344,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Leif Johansson

540,000

Pascal Soriot

3,344,000

Marc Dunoyer

296,000

Ruud Dobber

--

Caroline Hempstead

--

Paul Hudson

--
As Of 30 Dec 2013
Search Stocks